The emergence and spread of the B.1.1.529 lineage of SARS-CoV-2, the cause of coronavirus disease 2019 (Covid-19), has caused an unprecedented number of infections worldwide in a short period.1,2 Emerging evidence suggests that omicron causes less severe disease than previous variants of concern (VOC), probably due to lower virulence, infection-acquired immunity, and higher vaccination coverage.3–6 However, its high transmissibility and ability to partially evade the immune response induced has been associated with a substantial increase in severe Covid-19 cases globally.2 The absolute number of pediatric hospital admissions has also surpassed previous waves,4,7,8 straining healthcare systems even further. The increase may be related to higher transmissibility of omicron, less use of facemasks in children, and, especially concerning, lower vaccination rates among children.
Policymakers urgently need evidence of the effectiveness of Covid-19 vaccines in preventing severe clinical presentations of Covid-19 in children to balance the costs and benefits of mass vaccination campaigns. While the risk of severe Covid-19 in healthy children is substantially lower than among adults, vaccinating children may reduce community transmission, avoid potentially life-threatening presentations such as multisystemic inflammatory syndrome (MIS-C), and prevent long-term consequences of SARS-CoV-2 infection.9 Although numerous countries are vaccinating children, few have authorized Covid-19 vaccines for children under five, and some have restricted vaccines for children older than 12 years.10 Evidence of the efficacy or effectiveness of Covid-19 vaccines in children is limited, primarily related to mRNA vaccines, and only one study was conducted during the omicron outbreak.11–14 To the best of our knowledge, there is no evidence of vaccine effectiveness against Covid-19 in children under five years. Furthermore, recent research suggests that several Covid-19 vaccine platforms provide limited protection against infection and symptomatic disease caused by the omicron variant but were more effective against severe disease.15–17 These studies have examined vaccine protection against omicron in adult populations but are consistent with preliminary, unpublished results from a study in children 5 to 12 years.13
Leveraging a population-based cohort of children aged 3 to 5 years, we estimated the effectiveness of the complete primary immunization schedule (two doses, 28 days apart) of an inactivated SARS-CoV-2 vaccine, CoronaVac, to prevent laboratory-confirmed Covid-19, hospitalization, and admission to an intensive care unit (ICU). We estimated vaccine effectiveness using inverse probability-weighted survival regression models to estimate hazard ratios of complete immunization (starting 14 days after the second dose) over the unvaccinated status, accounting for time-varying vaccination exposure and available clinical, demographic, and socioeconomic confounders at baseline.
Our study cohort included 516,250 children aged 3 to 5 years affiliated to the Fondo Nacional de Salud (FONASA), the public national healthcare system. 490,694 children had received two doses of CoronaVac, 28 days apart between December 6, 2021, and February 26, 2022, or did not receive any Covid-19 vaccination. We excluded children who had probable or confirmed Covid-19 according to reverse-transcription polymerase-chain-reaction assay for SARS-CoV-2 or antigen test before December 6, 2021 (Supplementary Figure S1). The cohort characteristics are described in Supplementary Tables S1 and S2. Vaccination rollout was organized through a public schedule; children needed to show up at their nearest vaccination site with their national ID card (Supplementary Figure S2). The study period enclosed the omicron outbreak in Chile (Supplementary Tables S3 and S4, Fig.S3)
The estimated adjusted vaccine effectiveness for CoronaVac in children aged 3 to 5 years during the omicron outbreak was 38.2% (95% CI, 36.5–39.9) for the prevention of Covid-19, 64.6% (95% CI, 49.6–75.2) for the prevention of hospitalization, and 69.0% (95% CI, 18.6–88.2) for the prevention of Covid-19-related ICU admission (Table 1). We did not estimate vaccine effectiveness against fatal outcomes because only two deaths were observed in the unvaccinated group on February 26, 2022.
Table 1
Effectiveness of the CoronaVac Covid-19 vaccine in preventing Covid-19 outcomes among children 3–5 years of age in the study cohort according to immunization status, December 6, 2021, through February 26, 2022*
Immunization status | | Cases | | Vaccine effectiveness (95% CI) |
| Person-days | No. | Incidence rate | | Weighted, standard | Weighted, stratified |
| | | 1000 person-days | | adjustment † | analysis † |
Covid-19 | |
Unvaccinated | 29,404,535 | 7,555 | 0.2569 | | – | – |
CoronaVac (3–5 year.) | 18,499,492 | 4,562 | 0.2466 | | 37.9 | 38.2 |
(≥ 14 days after 2 dose) | | | | | (36.1 ; 39.6) | (36.5 ; 39.9) |
Hospitalization | |
Unvaccinated | 29,579,595 | 62 | 0.0021 | | – | – |
CoronaVac (3–5 year.) | 18,990,209 | 23 | 0.0012 | | 65.2 | 64.6 |
(≥ 14 days after 2 dose) | | | | | (50.4 ; 75.6) | (49.6 ; 75.2) |
Admission to ICU | |
Unvaccinated | 29,580,825 | 9 | 0.0003 | | – | – |
CoronaVac (3–5 year.) | 18,993,888 | 3 | 0.0002 | | 68.8 | 69.0 |
(≥ 14 days after 2 dose) | | | | | (18.0 ; 88.1) | (18.6 ; 88.2) |
* Covid-19 denotes coronavirus disease 2019, CI denotes confidence intervals, yr. denotes years. We classified participants' status into two categories during the study period: unvaccinated and fully immunized (≥ 14 days after receiving the second dose with CoronaVac). The days between the first dose vaccine administration and the full immunization were excluded from the at-risk person-time. We provide the results for the standard and stratified versions of the Cox hazards model using inverse probability of treatment weighting. |
† The analyses were adjusted for age, sex, region of residence, health insurance category (a proxy of household income), nationality, and whether the patient had underlying conditions that have been associated with severe Covid-19 in children, coded as described in Table S1. The standard and stratified versions of the extended Cox proportional-hazards model were fit to test the robustness of the estimates to model assumptions. |
Our estimates provide evidence of vaccination effectiveness in children aged 3 to 5 years during the omicron outbreak in Chile. These results are substantially lower than recent preliminary estimates of the effectiveness of two-dose vaccination of CoronaVac in children 6 to 16 years, in a period when B.1.617.2 (Delta) was the predominant circulating SARS-CoV-2 variant.14 In that study, the estimated effectiveness in children 6 to 16 years was 74.5% (95% CI, 73.8–75.2) for the prevention of Covid-19, 91.0% (95% CI, 87.8–93.4) for the prevention of hospitalization, and 93.8% (95% CI, 87.8–93.4) for the prevention of Covid-19-related ICU admission. The estimates for the subgroup of children aged 6–11 were 75.8% (95% CI, 74.7–76.8) for the prevention of Covid-19 and 77.9% (95% CI, 61.5–87.3) for the prevention of hospitalization.14 While the estimates are not directly comparable, the lower estimated vaccine effectiveness could be due to omicron or because the cohort included younger children.
Recent research suggests that vaccines may be less effective against omicron. Consistent with our results, an unpublished study in New York,13 found that the vaccine effectiveness of BNT162b2 for the prevention of Covid-19 and hospitalization decreased from 66–51% and from 85–73% for children aged 12–17 years, respectively. The drop was more considerable among children 5 to 11 years; protection against Covid-19 fell from 68–12%, and protection against hospitalization fell from 100–48%.13 Results among adults tell the same story. Early data from South Africa reported that BNT162b2 protection against Covid-19 related hospitalization decreased from 93–70% among adults.15 Among adults in the United Kingdom, two doses of ChAdOx1 nCoV-19 provided no detectable protection against the omicron variant after 20 weeks, and two doses of BNT162b2 were only 8.8% effective against omicron after 25 weeks.16 The study suggests a BNT162b2 or mRNA-1273 booster substantially increased protection against omicron.16 Similarly, a study that evaluated serum neutralization against omicron or D614G variant among adult participants with the mRNA-1273 vaccine primary series observed neutralization titers 35 times lower for omicron.17
Children’s age could also potentially affect vaccine effectiveness estimates for severe disease, as suggested by older children in recent unpublished studies in New York13 and Chile.14 Furthermore, clinical trials for Moderna’s mRNA-1273 and Pfizer-BioNTech’s BNT162b2 in children six months to under five years old are being conducted. Preliminary results for two 3 µg dose schedule, 21 days apart, of the BNT162b2 in children 2 to < 5 years old found disappointing results, although the immune response of children between six months and two years was comparable to that of young adults.18 Data from the mRNA-1273 vaccine in children have not yet been released.
Observational studies have limitations. Selection bias could affect vaccine effectiveness estimates if the vaccinated and unvaccinated groups are systematically different. We partially addressed this issue by adjusting our estimates with observable confounders that may affect vaccination and the risk of Covid-19. However, we do not have data to assess whether vaccinated and unvaccinated children or their caregivers differ in some unobservable characteristics, such as compliance with Covid-19 protocols. Another limitation in our study relates to genomic surveillance capabilities. The Ministry of Health’s strategy has focused on detecting variants of concern through traveler and community surveillance but uses non-probabilistic sampling (Supplementary Fig.S3, Tables S3 and S4).
To our advantage, data were collected during the omicron outbreak, with the highest transmission rates since the beginning of the pandemic. Vaccination rollout was quick and had high uptake (Supplementary Figure S2). Our estimated vaccine effectiveness reflects a “real-life” situation by including the challenges public health officials face in the field, such as a more diverse set of participants (e.g., with underlying conditions), schedule compliance, logistics, and cold chains. These estimates may be essential for decision making as a complement to controlled clinical trials.
Our results show that the effectiveness of CoronaVac in children 3 to 5 years against Covid-19 during the omicron was modest, although protection against severe disease remained high.